Article Sidebar
Views PDF: 161
EVALUATING THE RESULT OF GAMMA KNIFE RADIOSURGERY CONCURRENT WITH PEMETREXED AND CARBOPLATIN COMBINATION (PC) FOR BRAIN METASTASES OF NON SMALL CELL LUNG CANCER
Main Article Content
Abstract
Purpose: This study aimed at evaluating clinical, subclinical characteristics and resuls of treatment on patients who underwent Gamma Knife radiosurgery concurrent with Pemetrexed and Carboplatin conbination for brain metastases of non small cell lung cancer (NSCLC) at K Hospital and the Nuclear Medicine and Oncology Center, Bach Mai Hospital. Patients andMethod: Retrospective combination prospective descriptive cross sectionnal study on 65 NSCLC non squamous cell with brain metastases were underwent Gamma Knife radiosurgery concurrent with Pemetrexed and Carboplatin conbination at K Hospital and the Nuclear Medicine and Oncology Center, Bach Mai Hospital from January 2018 to July 2021. Results: The mean age was 58,3 ± 9,2 years old, males accounted for 86,2%. Clinical characteristics: intracranialhypertension (72,3%), dry cough (61,9%), no mental symptoms (18,5%). MRI features: tumors located in hemisphere (66,2%), three tumor (44,6%), above 10mm in diameter of the brain metastases (89,2%). The overall response rate (ORR) was 35,4%, the objective cerebral response rate was 70,7%, the extracerebral response rate was 36,9%. The disease control rate (DCR) of cerebral lesions was 90,7%. The median of progression free survival (PFS) was 10,3 months. The median progression-free survival of brain metastases was 10,8 months.Common toxicity were anemia (49,2%), nausea (40%), vomiting (20%), hepatic insufficiency (12,3%). Conclusions: Gamma Knife radiosurgery concurrent with Pemetrexed and Carboplatin combination is effective in treating brain metastases of non small cell lung cancer with a high safety.
Article Details
Keywords
non small cell lung cancer, brain metastases, chemotherapy, gamma knife radiosurgery, pemetrexed
References
2. Moro-Sibilot D, Smit E, de Castro Carpeño J, et al. Non-small cell lung cancer patients with brain metastases treated with first-line platinum-doublet chemotherapy: Analysis from the European FRAME study. Lung cancer (Amsterdam, Netherlands). 2015;90(3):427-432.
3. Phạm Văn Thái. Nghiên cứu điều trị ung thư phổi không tế bào nhỏ di căn não bằng hóa xạ trị [Luận văn tiến sĩ y học], Trường Đại học Y Hà Nội; 2015.
4. Delattre JY, Krol G, Thaler HT, Posner JB. Distribution of brain metastases. Archives of neurology. 1988;45(7):741-744.
5. Langer CJ, Gadgeel SM, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. The Lancet Oncology. 2016;17(11):1497-1508.
6. Barlesi F, Gervais R, Lena H, et al. Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01). Annals of oncology: official journal of the European Society for Medical Oncology. 2011;22(11):2466-2470.
7. Gerosa M, Nicolato A, Foroni R, Tomazzoli L, Bricolo A. Analysis of long-term outcomes and prognostic factors in patients with non-small cell lung cancer brain metastases treated by gamma knife radiosurgery. Journal of neurosurgery. 2005; 102 Suppl:75-80.
8. Bailon O, Chouahnia K, Augier A, et al. Upfront association of carboplatin plus pemetrexed in patients with brain metastases of lung adenocarcinoma. Neuro-oncology. 2012;14(4):491-495.